Edgewise Therapeutics Inc (NASDAQ: EWTX) on Tuesday, soared 0.47% from the previous trading day, before settling in for the closing price of $14.82. Within the past 52 weeks, EWTX’s price has moved between $10.60 and $38.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -20.82%. With a float of $74.00 million, this company’s outstanding shares have now reached $95.21 million.
The firm has a total of 110 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Edgewise Therapeutics Inc is 29.65%, while institutional ownership is 71.49%. The most recent insider transaction that took place on May 02 ’25, was worth 25,520. In this transaction Chief Scientific Officer of this company sold 1,551 shares at a rate of $16.45, taking the stock ownership to the 18,521 shares. Before that another transaction happened on May 02 ’25, when Company’s General Counsel sold 1,930 for $16.45, making the entire transaction worth $31,757. This insider now owns 6,531 shares in total.
Edgewise Therapeutics Inc (EWTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.53% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
Edgewise Therapeutics Inc (EWTX) is currently performing well based on its current performance indicators. A quick ratio of 20.99 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.93 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
Analysing the last 5-days average volume posted by the [Edgewise Therapeutics Inc, EWTX], we can find that recorded value of 1.17 million was lower than the volume posted last year of 1.54 million. As of the previous 9 days, the stock’s Stochastic %D was 27.11%. Additionally, its Average True Range was 1.27.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 18.83%, which indicates a significant decrease from 30.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.29% in the past 14 days, which was lower than the 82.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.59, while its 200-day Moving Average is $24.68. Now, the first resistance to watch is $15.13. This is followed by the second major resistance level at $15.37. The third major resistance level sits at $15.76. If the price goes on to break the first support level at $14.51, it is likely to go to the next support level at $14.12. Now, if the price goes above the second support level, the third support stands at $13.88.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
Market capitalization of the company is 1.57 billion based on 105,200K outstanding shares. Right now, sales total 0 K and income totals -133,810 K. The company made 0 K in profit during its latest quarter, and -40,800 K in sales during its previous quarter.
